Prithwish Banerji Succeeds Murari Ranganathan As Commercial Director Of Women’s Health, Metabolics & International Business At Abbott India

Prithwish Kumar Banerji has been appointed as Commercial Director of Women’s Health, Metabolics, and International Business at Abbott India Limited with effect from January 3, 2025.

Banerji will succeed Murari Ranganathan, who is set to step down from the same position with effect from February 25, 2025, to pursue opportunities outside the company.

Banerji has nearly 28 years of experience in a commercial role. He joins Abbott from Cipla, where he was part of the Cipla Leadership Group and served as Vice President and Vertical Head for their respiratory portfolio of Nebulisation and Immunotherapy. His experience spans sales, marketing, strategic business planning, and execution. Before Cipla, Prithwish worked with pharmaceutical MNCs and FMCG organisations such as Unilever and GSK Consumer Healthcare. He also had a brief tenure with Abbott Diabetes Care as National Sales Manager. Prithwish has experience in launching new entrants in the Indian pharmaceutical market, patent product launches, and developing go-to-market models across pharmaceuticals, OTC/OTX, and FMCG. He holds a degree in Geology from St. Xavier’s College, Ranchi, and completed an Executive Management Program from IIM Lucknow.